Photo from wikipedia
Iscalimab, an anti-CD40 monoclonal antibody, showed preliminary efficacy for the treatment of primary Sjögren syndrome (pSS) in a phase II placebo-controlled trial (n = 44). Of the two administration routes… Click to show full abstract
Iscalimab, an anti-CD40 monoclonal antibody, showed preliminary efficacy for the treatment of primary Sjögren syndrome (pSS) in a phase II placebo-controlled trial (n = 44). Of the two administration routes tested (intravenous and subcutaneous), only intravenous iscalimab resulted in a significant reduction in the EULAR Sjögren’s syndrome disease activity index (ESSDAI) score after 12 weeks of treatment compared with placebo (95% CI 0.96–9.46; one-sided P = 0.0090). Only two severe adverse events were reported across all groups, neither of which was related to iscalimab.
Journal Title: Nature Reviews Rheumatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!